LncmiRHG-MIR100HG: A new budding star in cancer

Yingnan Wu1, Zhenzhen Wang1, Shan Yu2

  • 1Cancer Center, Department of Ultrasound Medicine, Zhejiang Provincial People's Hospital, Affiliated People's Hospital of Hangzhou Medical College, Hangzhou, China.

Frontiers in Oncology
|October 10, 2022
PubMed

Insights

MIR100HG, a long noncoding RNA, is a critical regulator in various cancers, acting as an oncogene or tumor suppressor. Its dysregulation correlates with poor prognosis, highlighting its diagnostic and therapeutic potential.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • MIR100HG (lncRNA mir-100-let-7a-2-mir-125b-1 cluster host gene) is a newly identified regulator in cancer.
  • Its expression is altered in numerous cancers, where it can function as an oncogene or tumor suppressor.

Purpose of the Study:

  • To review the characteristics and roles of MIR100HG in diverse cancers.
  • To summarize MIR100HG's molecular mechanisms, pathways, and involvement in chemoresistance.
  • To discuss current research progress and future directions for MIR100HG in cancer therapy.

Main Methods:

  • Literature review and synthesis of existing research on MIR100HG in cancer.
  • Analysis of MIR100HG's correlation with clinicopathological features and prognosis.
  • Exploration of MIR100HG's molecular functions and signaling pathways.

Main Results:

  • MIR100HG exhibits dual roles (oncogenic/tumor-suppressive) across different cancer types.
  • Dysregulated MIR100HG expression is significantly associated with poor prognosis and specific clinicopathological features.
  • MIR100HG influences key cancer cell biology processes and pathways, including chemoresistance.

Conclusions:

  • MIR100HG is a significant factor in cancer development and progression.
  • Understanding MIR100HG's multifaceted roles is crucial for developing targeted cancer therapies.
  • Further research into MIR100HG may lead to novel diagnostic and therapeutic strategies for cancer patients.

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.8K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.1K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.7K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.1K